Nikolai Kragøe Andresen

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Bjerre et al. · Nature Medicine · 2022 · 76 citations · Full text

ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

Jon Amund Kyte, Nikolai Kragøe Andresen, HG Russnes et al. · Journal of Translational Medicine · 2020 · 44 citations · Full text

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur et al. · Journal for ImmunoTherapy of Cancer · 2024 · 13 citations · Full text

Gut microbiota diversity is prognostic and associated with benefit from chemo‐immunotherapy in metastatic triple‐negative breast cancer

Andreas Ullern, Kristian Holm, Andreas Hagen Røssevold et al. · Molecular Oncology · 2024 · 13 citations · Full text

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the <scp>ALICE</scp> and <scp>ICON</scp> trials

Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen et al. · Molecular Oncology · 2024 · 12 citations · Full text